Literature DB >> 34916890

Single-Arm 8-Week Ad Libitum Self-Prepared Paleo Diet Reduces Cardiometabolic Disease Risk Factors in Overweight Adults.

Melissa M Markofski1,2,3,4, Kristofer Jennings1,2,3,4, Chad Dolan1,2,3,4, Natalie A Davies1,2,3,4, Emily C LaVoy1,2,3,4, Edward J Ryan1,2,3,4, Andres E Carrillo1,2,3,4.   

Abstract

The paleo diet is popular among the general population due to promoted weight loss and disease prevention benefits. We examined the effectiveness of a self-administered paleo diet in improving cardiometabolic disease risk factors. Overweight, physically inactive but otherwise healthy adults (males = 4, females = 3, age 32.7 ± 4.9 years, body mass index [BMI] 29.4 ± 2.4 kg/m2) habitually eating a traditional Western diet (1853.4 ± 441.2 kcal; 34.0% carbohydrate; 41.4% fat; 19.2% protein) completed an ad libitum self-administered paleo diet for 8 weeks. Height, weight, blood pressure, and a fasting blood sample were collected pre- and post-paleo dietary intervention. Blood samples were analyzed for fasting cardiometabolic disease biomarkers-including brain-derived neurotropic factor (BDNF), fibroblast growth factor (FGF) 21, and leptin. After 8 weeks, body mass (-5.3 kg, P = .008), BMI (-1.7 kg/m2, P = .002), serum leptin (-56.2%, P = .012), serum FGF21 (-26.7%, P = .002), and serum BDNF (-25.8%, P = .045) significantly decreased. Systolic and diastolic blood pressure were unchanged following the paleo dietary intervention (P > .05). Average energy intake (-412.6 kcal, P = .016) significantly decreased with the paleo dietary intervention mostly due to a reduction in carbohydrate consumption (-69.2 g; P = .003). An 8-week self-administered paleo dietary intervention was effective in improving cardiometabolic disease risk factors in a healthy, physically inactive overweight adult population.
© 2019 The Author(s).

Entities:  

Keywords:  dietary intervention; inflammation; metabolic syndrome; young adults

Year:  2019        PMID: 34916890      PMCID: PMC8669899          DOI: 10.1177/1559827619866157

Source DB:  PubMed          Journal:  Am J Lifestyle Med        ISSN: 1559-8276


  51 in total

1.  2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Robert H Eckel; John M Jakicic; Jamy D Ard; Janet M de Jesus; Nancy Houston Miller; Van S Hubbard; I-Min Lee; Alice H Lichtenstein; Catherine M Loria; Barbara E Millen; Cathy A Nonas; Frank M Sacks; Sidney C Smith; Laura P Svetkey; Thomas A Wadden; Susan Z Yanovski; Karima A Kendall; Laura C Morgan; Michael G Trisolini; George Velasco; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

2.  Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects.

Authors:  Mirjam A Lips; Gerrit H de Groot; Frits J Berends; Renee Wiezer; Bart A van Wagensveld; Dingeman J Swank; Arijan Luijten; Ko Willems van Dijk; Hanno Pijl; Peter L M Jansen; Frank G Schaap
Journal:  Clin Endocrinol (Oxf)       Date:  2014-06-12       Impact factor: 3.478

3.  Dietary inflammatory potential is linked to cardiovascular disease risk burden in the US adult population.

Authors:  Stefanos Tyrovolas; Ai Koyanagi; Georgios A Kotsakis; Demosthenes Panagiotakos; Nitin Shivappa; Michael D Wirth; James R Hébert; Josep Maria Haro
Journal:  Int J Cardiol       Date:  2017-05-01       Impact factor: 4.164

4.  Body mass index categories and mortality risk in US adults: the effect of overweight and obesity on advancing death.

Authors:  Luisa N Borrell; Lalitha Samuel
Journal:  Am J Public Health       Date:  2014-01-16       Impact factor: 9.308

Review 5.  Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology.

Authors:  Huating Li; Jing Zhang; Weiping Jia
Journal:  Front Med       Date:  2013-01-28       Impact factor: 4.592

6.  Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects.

Authors:  M Maffei; J Halaas; E Ravussin; R E Pratley; G H Lee; Y Zhang; H Fei; S Kim; R Lallone; S Ranganathan
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

7.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

8.  Various oscillation patterns of serum fibroblast growth factor 21 concentrations in healthy volunteers.

Authors:  Sang Ah Lee; Eunheiu Jeong; Eun Hee Kim; Mi-Seon Shin; Jenie Yoonoo Hwang; Eun Hee Koh; Woo Je Lee; Joong-Yeol Park; Min-Seon Kim
Journal:  Diabetes Metab J       Date:  2012-02-17       Impact factor: 5.376

9.  Benefits of a Paleolithic diet with and without supervised exercise on fat mass, insulin sensitivity, and glycemic control: a randomized controlled trial in individuals with type 2 diabetes.

Authors:  Julia Otten; Andreas Stomby; Maria Waling; Andreas Isaksson; Anna Tellström; Lillemor Lundin-Olsson; Søren Brage; Mats Ryberg; Michael Svensson; Tommy Olsson
Journal:  Diabetes Metab Res Rev       Date:  2016-06-30       Impact factor: 4.876

10.  Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease.

Authors:  Yun Shen; Xiaojing Ma; Jian Zhou; Xiaoping Pan; Yaping Hao; Mi Zhou; Zhigang Lu; Meifang Gao; Yuqian Bao; Weiping Jia
Journal:  Cardiovasc Diabetol       Date:  2013-08-28       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.